Preview

Медицинский Совет

Расширенный поиск

Ведолизумаб в лечении воспалительных заболеваний кишечника: кому и как?

https://doi.org/10.21518/2079-701X-2018-14-44-49

Полный текст:

Аннотация

Статья посвящена применению ведолизумаба – селективного ингибитора α4β7-интегринов – в лечении воспалительных заболеваний кишечника (язвенного колита и болезни Крона). Приведены результаты клинических испытаний препарата и опыт применения ведолизумаба в реальной клинической практике. Предоставлены последние доступные сведения о профиле безопасности лекарственного средства. Рассмотрены практические аспекты терапии, такие как определение показаний к лечению, тактика при потере ответа, необходимость комбинации ведолизумаба с иммуносупрессорами, применение препарата у особых категорий пациентов.

Об авторах

А. О. Головенко
ООО «Глобал Медикал Систем»
Россия

к.м.н., гастроэнтеролог,

Москва



О. В. Головенко
ФГБОУ ДПО «Российская медицинская академия непрерывного медицинского образования» Минздрава России
Россия

д.м.н., профессор кафедры,

Москва



Список литературы

1. Allez M, Karmiris K, Louis E, Van Assche G, BenHorin S, Klein A et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis, 2010, 4(4): 355-66.

2. Pereira R, Faria R, Lago P, Torres T. Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases. Curr Drug Saf, 2017, 12(3): 162-170.

3. Pérez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, Perez-Alvarez R, Brito-Zerón P et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf, 2017, 16(11): 1255-1271.

4. Katsanos AH, Katsanos KH. Inflammatory bowel disease and demyelination: more than just a coincidence? Expert Rev Clin Immunol, 2014, 10(3): 363-73.

5. Harbord M, Eliakim К, Bettenworth В, Karmiris К, Katsanos К, Kopylov U et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis, 2017, 11(7): 769–784.

6. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J et al. Third European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis, 2017, 11(7): 3–25.

7. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol, 2018, 113(4): 481-517.

8. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А., Шифрин О.С., Абдулганиева Д.И. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология, 2017, 2(60): 7-29.

9. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med, 2005, 353: 375–381.

10. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med, 2009, 361: 1067–1074.

11. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2013, 369: 699–710.

12. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med, 2013, 369: 711–721.

13. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology, 2014, 147: 618–627.

14. Wang MC, Zhang LY, Han W, Shao Y, Chen M, Ni R et al. PRISMA–efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore), 2014, 93(28): e326.

15. Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE et al. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis, 2017, 1, 11(4): 400-411.

16. Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn WJ, Sands BE et al. Long-term Efficacy of Vedolizumab for Crohn’s Disease. J Crohns Colitis, 2017, 1, 11(4): 412-424.

17. Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K et al. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis. J Crohns Colitis, 2017, 1, 11(9): 1085-1089.

18. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol, 2012, 10(9): 1002-1007.

19. Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X et al. Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol, 2016, 14(11): 1593- 1601.

20. Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X et al. OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther, 2017, 46(3): 310-321.

21. Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol, 2017, 52(6-7): 722-729.

22. Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S. Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study. Aliment Pharmacol Ther, 2016, 43(10): 1090-1102.

23. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K et al. The Real-World Effectiveness and Safety of Vedolizumab for ModerateSevere Crohn’s Disease: Results From the US VICTORY Consortium. Am J Gastroenterol, 2016, 111(8): 1147-55.

24. Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S et al. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli RealWorld Experience. Inflamm Bowel Dis, 2017, 23(3): 404-408.

25. Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis, 2015, 21(12): 2879-85.

26. Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis, 2018, 50(7): 675-681.

27. Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V et al. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci, 2017, 62(6): 1590- 1596.

28. Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease — a prospective multicenter observational study. Aliment Pharmacol Ther, 2016, 44(11-12): 1199- 1212.

29. Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH et al. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis, 2016, 10(4): 402-409.

30. Samaan MA, Pavlidis P, Johnston E, Warner B, Digby-Bell J, Koumoutsos I et al. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol, 2017, 8(3): 196-202.

31. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut, 2017, 66(5): 839-851.

32. Rahier JF, Magro F, Abreu C, Armuzzi A, BenHorin S, Chowers Y et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis, 2014, 8(6): 443-68.

33. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol, 2014, 76(6): 802-12.

34. Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther, 2017, 46(1): 3-15.

35. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol, 2001, 33(4): 289- 94.

36. Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017, 1(59): 6–30.

37. Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B et al. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age. Adv Ther, 2017, 34: 542–59.

38. Navaneethan U, Edminister T, Zhu X, Kommaraju K, Glover S. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis, 2017, 23: E17.

39. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohn’s Colitis, 2017, 11(7): 769–784.

40. Feagan B, Lasch K, Lissoos T, Cao C, Wojtowicz A et al. Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases. J Clin Gastroenterol, 2018; doi. org/10.1016/j.cgh.2018.05.026 .

41. Feagan B, Rubin D, Danese S, Vermeire S, Abhyankar B, Sankoh S et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. J Clin Gastroenterol, 2017;15: 229–239.

42. Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. Inflam Bowel Dis, 2017; 23: 97–106

43. Faleck D, Shashi P, Meserve J, Rahal M, Kadire S, Tran G, et al. Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis. J Crohn’s Colitis, 2018, 12: S019.

44. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med, 2010, 15;362(15): 1383-95.

45. Gouynou C, Peyrin-Biroulet L. Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients. Aliment Pharmacol Ther, 2017, 46: 1019–1020.

46. Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M et al. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: a Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2018, Jun 20.


Просмотров: 73


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)